BioCryst Pharmaceuticals, Inc.

Total Valuation

BioCryst Pharmaceuticals, Inc. carries a market capitalization of 1.75B, placing it among publicly traded companies globally. Its enterprise value stands at 2.66B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

BioCryst Pharmaceuticals, Inc. currently has 254.01M shares outstanding.

Valuation Ratios

BioCryst Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 6.20. The price-to-sales ratio is 2.35, and the price-to-book ratio stands at -0.93.

Enterprise Valuation

On an enterprise value basis, BioCryst Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 73.31 and an EV/FCF ratio of 6.78. The EV/Sales ratio of 3.00 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 74.77 provides insight into valuation relative to core operating earnings.

Financial Position

BioCryst Pharmaceuticals, Inc. maintains a current ratio of 1.91, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -147.65, indicating conservative leverage, while an interest coverage ratio of -5.06 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, BioCryst Pharmaceuticals, Inc. has paid 3.81M in income taxes, reflecting an effective tax rate of 22.48.

Stock Price Statistics

BioCryst Pharmaceuticals, Inc.'s stock has declined approximately -25.46917% over the past 52 weeks. The 50-day moving average sits at 9.13, while the 200-day moving average is 7.92.

Income Statement

Over the trailing twelve months, BioCryst Pharmaceuticals, Inc. generated 885.72M in revenue and converted that into -457.98M in net income, yielding earnings per share of -2.03. EBITDA reached -380.32M, while operating income came in at -381.84M.

Balance Sheet

BioCryst Pharmaceuticals, Inc. holds 238.40M in cash and equivalents against 817.77M in total debt, resulting in a net debt position of 630.79M. Total book value stands at -2.23B, with working capital of 178.23M providing operational flexibility.

Cash Flow

BioCryst Pharmaceuticals, Inc. produced 313.10M in operating cash flow over the past twelve months. After subtracting -2.73M in capital expenditures, free cash flow totaled 310.37M - equivalent to 1.42 per share.

Margins

BioCryst Pharmaceuticals, Inc. operates with a gross margin of 97.76, reflecting its pricing power and cost economics. The operating margin of -43.11 and net profit margin of -51.71 provide insight into operational efficiency.

Dividends & Yields

Scores

BioCryst Pharmaceuticals, Inc. posts an Altman Z-Score of -5.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.